The Review Of
DIABETIC
STUDIES OPEN ACCESS

Pharmacological Approaches To Oral-Systemic Diseases: A Clinical Review Integrating Dentistry And Pharmacy

[1-]Mohammed Saleh Mutab Alshaqi , [2-]Mohammed Ayed Saad Alghamdi , [3-]Ali Abdullah Mohammed Alshamrani , [4-]Hassan Mohammed Ali Alharthi , [5-]Ghazi Abdullah Mohammed Alshamrani , [6-]Ali Saleh Hassan Alghamdi , [7-]Fardan Hamed Mohammad Alameri , [8-]Saleh Hassan Saeed Almontashru , [9-]Abdulaziz Ali Almontashiri , [10-]Majed Abdullah Hazzah Alsuhimi , [11-]Ali Abdullah Ahmed Alshamrani

**Corresponding author e-mail: faya.h.asiri@gmail.com (Faya Hadi Asseri)*
Received date: 20 June 2025 Revised date: 28 June 2025. Accepted date: 18 July 2025

Abstract:

Background: Oral diseases are biofilm-mediated, immuno-inflammatory conditions that persist into later life and serve as reservoirs for systemic infection and inflammation. Their microbiology—ranging from β-lactamase–producing anaerobes (e.g., Prevotella, Fusobacterium) to intracellular periodontal pathogens (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis) and opportunistic yeasts (Candida spp.)—creates therapeutic challenges that demand antimicrobial stewardship and interprofessional coordination.
Aim: To synthesize pharmacological approaches for preventing and treating oral–systemic diseases, integrating dental procedures with pharmacist-guided antimicrobial, antifungal, antiviral, and host-modulatory strategies, with particular emphasis on medically compromised patients and cardiovascular risk mitigation.
Methods: Narrative clinical review of pathogen ecology, disease mechanisms, and treatment paradigms across odontogenic infections, periodontal and peri-implant diseases, cancer therapy–related toxicities, and preventive pharmacology, highlighting collaborative models between dentistry and pharmacy.
Results: Effective management hinges on procedural source control supplemented by targeted pharmacotherapy (e.g., penicillin plus metronidazole for β-lactamase–associated anaerobes), locally delivered antimicrobials for periodontal pockets, azole or polyene therapy for candidosis with interaction surveillance, and antivirals for herpetic disease in high-risk hosts. Host modulation (e.g., Subantimicrobial-dose doxycycline) tempers matrix degradation. Pre-treatment dental clearance reduces sepsis and osteonecrosis risks in immunosuppressed or antiresorptive-treated patients. Preventive regimens combine mechanical biofilm control with adjunct antiseptics; chlorhexidine is effective short-term but limited by adverse effects, whereas triclosan-containing dentifrices demonstrate durable reductions in plaque/gingivitis and slower periodontal progression. Periodontal therapy aligns with reductions in systemic inflammatory markers and improved endothelial function.
Conclusion: Pharmacological strategies, embedded within structured dentist–pharmacist collaboration, reduce oral infectious burden, attenuate systemic inflammation, and safeguard complex medical therapies. Standardized protocols and outcome monitoring are essential to optimize whole-person health.
Keywords: oral–systemic link; antimicrobial stewardship; periodontal disease; odontogenic infection; peri-implantitis; candidosis; host modulation; chlorhexidine; triclosan; interprofessional care.

Introduction

Over the past half-century, sustained advances in the science and clinical practice of dentistry have markedly improved the preservation of natural dentitions across the lifespan. Yet, this success story intersects directly with the theme of Pharmacological Approaches to Oral–Systemic Diseases: A Clinical Review Integrating Dentistry and Pharmacy. Many teeth that are retained into later life are heavily restored and structurally compromised, leaving them susceptible to recurrent caries, endodontic failure, and restoration fracture. Concomitantly, an increasingly dentate aging population faces an elevated risk of periodontal disease, shifting the clinical objective from complete prevention to disease control. In routine care, the aspirational endpoint of enduring oral health is not always attainable; clinicians frequently aim to arrest progression, accepting that chronic, often asymptomatic, infections may persist despite therapy. Parallel trends—most notably the rising incidence of chronic or malignant mucosal disorders—underscore the mouth's role as a persistent nidus of infection and inflammation that contributes to systemic inflammatory load, influences multimorbidity, and affects overall well-being. In this context, coordinated dental–pharmacy strategies become pivotal for optimizing antimicrobial selection, minimizing resistance, and aligning local oral interventions with systemic health goals.

Central to an integrated clinical approach is an appreciation of the distinctive ecology of the oral microbiome. The oral cavity harbors a uniquely diverse community not replicated elsewhere in the body, with viridans group streptococci dominating the commensal flora in health. However, the microbiological profile shifts in disease states are relevant to both dental and medical therapeutics. In odontogenic infections, pus cultures commonly yield facultative anaerobic streptococci alongside anaerobic Gram-negative bacilli—particularly Prevotella and Fusobacterium spp. [1,2]. This pattern has direct pharmacological implications: a substantial fraction of Prevotella isolates worldwide now produce β-lactamases, rendering β-lactam monotherapy unreliable. Accordingly, combination regimens such as penicillin plus metronidazole are employed to broaden anaerobic coverage and overcome β-lactamase-mediated resistance, exemplifying the necessity of collaborative antimicrobial stewardship between dental clinicians and pharmacists to tailor therapy, mitigate collateral damage to the microbiome, and reduce resistance selection pressure.

Periodontal pathobiology further illustrates the oral–systemic interface and the challenges for antimicrobial efficacy. Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans and Porphyromonas gingivalis are canonical periodontal pathogens strongly linked to destructive periodontitis. Notably, both organisms can invade oral epithelial cells, a trait that facilitates immune evasion and diminishes antibiotic accessibility at the intracellular niche [3,4]. These features complicate chemotherapeutic strategies by limiting the effectiveness of agents with poor intracellular penetration, necessitating careful drug selection, dosing, and duration. They also highlight the value of adjunctive, non-pharmacological biofilm control (scaling and root planning, rigorous self-care) integrated with targeted systemic or local antimicrobials when indicated, always anchored in risk assessment and interprofessional coordination to balance benefits against adverse effects and resistance risks.

Beyond classic periodontal pathogens, biofilm-forming Actinomyces spp. occupy a dual role highly relevant to pharmacotherapy. As early colonizers, they constitute the structural backbone of dental plaque in health but are also implicated in disease contexts. Actinomyces species are consistently detected in peri-implantitis—an inflammatory–infectious condition affecting implant-supporting tissues that can culminate in implant loss [5]. Their presence within mature biofilms and peri-implant pockets underscores why mechanical disruption is indispensable and why antibiotic regimens, when used, must account for biofilm-associated tolerance. Moreover, Actinomyces can cause cervicofacial actinomycosis of the jaws, a chronic, suppurative infection that often demands prolonged, appropriately targeted antibiotic courses coupled with surgical management, again benefiting from pharmacy input on drug selection, dosing strategies, and monitoring for toxicity.

Fungal ecology in the oral cavity adds another layer to integrated care. Candida albicans remains the predominant yeast isolated orally, yet the relative prevalence of non-albicans Candida species has increased, particularly among medically fragile individuals. This epidemiological shift bears therapeutic significance, as species-level differences in antifungal susceptibility can influence the success of empiric therapy. For patients with complex comorbidities, polypharmacy, or xerostomia, pharmacists are essential partners in evaluating drug–drug interactions (e.g., azole antifungals with cardiovascular or psychotropic agents), anticipating pharmacokinetic variations, and advising on formulation choices that enhance mucosal exposure while limiting systemic toxicity.

Taken together, these microbiological and clinical realities reinforce the need for a deliberately integrated model in which dentists and pharmacists co-manage antimicrobial and adjunctive pharmacotherapies tailored to the unique ecology of the oral cavity and the patient's systemic context. By aligning pathogen-directed treatment (e.g., β-lactam plus metronidazole for β-lactamase–producing anaerobes [1,2]; agents with better intracellular penetration when confronting epithelial invasion [3,4]) with rigorous biofilm control and vigilant monitoring, the care team can reduce the oral contribution to systemic inflammatory burden, preserve dental and implant function, and enhance overall health outcomes. In this way, pharmacological strategies become not merely adjuncts to dental procedures but integral components of comprehensive, system-aware clinical care [5].



Figure-1: The mouth of a male aged 58 years with severely damaged dentition and periodontitis. (Rautemaa, et al, 2007).



Figure-2: The mouth of a patient with severe stomatitis caused by chronic candidosis. The patient was diagnosed with an autoimmune disease against adrenal and parathyroid glands. (Rautemaa, et al, 2007).

Odontogenic Infections

Within the framework of Pharmacological Approaches to Oral–Systemic Diseases: A Clinical Review Integrating Dentistry and Pharmacy, odontogenic infections exemplify how local pathology in the oral cavity can escalate into serious systemic disease and thus demand tightly coordinated dental–medical–pharmacy management. Although the propagation of infection is often constrained by anatomic boundaries and fascial planes—such as muscle envelopes and osseous structures—these natural barriers can be breached, allowing posterior–inferior spread toward the larynx and, in severe cases, into the mediastinum [1].

A foundational therapeutic principle follows antibiotics alone are insufficient to eradicate odontogenic infections; durable resolution requires timely, definitive dental procedures (e.g., drainage, debridement, endodontic therapy, or extraction) to achieve source control. Pharmacotherapy therefore functions as a critical adjunct rather than a substitute, and—consistent with contemporary practice—

combination therapy with penicillin and metronidazole should be considered to extend coverage to anaerobic pathogens frequently implicated in these infections.

The clinical tempo of odontogenic infections can be alarmingly rapid, with airway compromise developing within hours. In such scenarios, early recognition and decisive airway management are paramount; patients may require urgent endotracheal intubation or surgical tracheostomy followed by intensive care support [1]. A paradigmatic illustration of the oral–systemic continuum is Lemierre's syndrome, a life-threatening septic condition that typically necessitates critical care. Fusobacterium necrophorum is commonly isolated, and the disease course may feature suppurative thrombophlebitis of the internal jugular vein with subsequent metastatic abscess formation in the lungs or brain [1]. From a pharmacological standpoint, these presentations underscore the necessity of prompt, appropriately targeted empiric therapy with reliable anaerobic activity, refined by culture data, while dental colleagues pursue source control. Pharmacists play a vital role in optimizing antimicrobial selection, dosing, and potential drug–drug interaction mitigation in acutely ill patients.

More broadly, the oral cavity constitutes a substantial reservoir of microorganisms capable of seeding distant foci; thus, any infection with organisms characteristic of oral flora should prompt clinicians to evaluate a possible odontogenic source [6–8]. Although brain abscesses attributable to oral microbes have been repeatedly reported [9], the classical systemic manifestation remains infective endocarditis due to viridans group streptococci. According to the infectious diseases register of the Finnish National Public Health Institute (http://www.ktl-fin/tartuntatautirekisteri), adult septicaemias caused by viridans streptococci have nearly doubled over the past decade, in parallel with the growing proportion of individuals remaining dentate throughout life; viridans streptococci currently rank as the fifth most common cause of septicaemia among adults in Finland. These epidemiological observations align squarely with the integrative thesis of this review: improvements in dental retention alter systemic infectious risk profiles, thereby heightening the importance of interprofessional surveillance, prevention, and pharmacological stewardship.

For infectious diseases physicians—and indeed for all clinicians managing systemic infections of uncertain origin—oral health status warrants deliberate attention. Odontogenic foci often remain clinically silent yet can intermittently produce bacteraemia even in the absence of overt symptoms. Routine daily activities and minor dental interventions alike can transiently introduce bacteria into the bloodstream: toothbrushing, supragingival calculus removal, endodontic procedures, and oral surgery have all been associated with bacteraemia in otherwise healthy individuals [10,11]. In this light, integrated care pathways become essential. Dentists identify and eliminate niduses; physicians evaluate systemic consequences and indications for hospital care; and pharmacists guide antimicrobial regimens that balance efficacy against the risks of resistance, adverse events, and interactions with concomitant therapies—particularly in patients with comorbidities or polypharmacy.

Finally, oral manifestations may provide sentinel clues to underlying systemic disease, reinforcing the bidirectional nature of the oral–systemic axis. For example, oral candidosis without an alternative explanation should raise clinical suspicion for human immunodeficiency virus infection, potentially at a stage when CD4+ counts remain relatively preserved and other systemic signs are minimal. Here again, the integrative model advocated in this review facilitates timely diagnosis and coordinated management: dental recognition of atypical mucosal disease prompts medical assessment, while pharmacy expertise supports appropriate antifungal selection and safety monitoring. Collectively, these considerations affirm that effective management of odontogenic infections—and their systemic ramifications—rests on the synergy of procedural source control and judicious pharmacotherapy within an interprofessional, patient-centered framework [1,6–8,9,10,11].

Within the remit of Pharmacological Approaches to Oral–Systemic Diseases: A Clinical Review Integrating Dentistry and Pharmacy, the care of the medically compromised patient epitomizes the need for coordinated, system-aware oral healthcare. Contemporary gastroenterological and rheumatological disorders are increasingly managed with moderate-to-severe immunosuppressive agents, while malignancies and their cytotoxic or targeted therapies affect a growing proportion of the population. In these contexts, oral health becomes a foundational component of comprehensive medical care. Chronic oral infections often smoulder with only minor local symptoms and remain contained so long as host defences and tissue responses are intact. In the immunocompromised host, however, even a clinically quiescent focus—such as chronic osteitis or mild Candida mucositis—may convert into a source of

fulminant, disseminated infection with life-threatening potential [12,13]. Accordingly, an essential pharmacological and surgical principle in integrated care is the pre-emptive eradication of identifiable oral foci before the initiation of immunosuppression or cytotoxic therapy, thereby reducing infectious risk at precisely the moment systemic defences are deliberately attenuated.

The same preventive logic applies beyond oncology or autoimmune disease management. Before cardiac surgery or the placement of joint prostheses, latent dental and periodontal infections can provide a microbial reservoir for haematogenous seeding, with potential implications for postoperative complications and prosthetic failure. It is therefore prudent to ensure that all remediable oral foci are eliminated in advance of such procedures [14]. As a minimum standard, radiographic evaluation of the teeth, their supporting alveolar bone, and the jaws should be undertaken to detect periapical pathology, retained roots, or occult osteitis. This imaging should be paired with a meticulous clinical examination by a dentist experienced in oral medicine, so that pharmacological plans—antibiotic prophylaxis, antifungal strategies, analgesia, and xerostomia management—can be tailored to the patient's systemic status and treatment timeline.

Among patients receiving cancer therapies, poor baseline oral health and extensive therapy-associated stomatitis are both common and highly morbid [15–18]. Ulcerated or inflamed mucosa not only causes significant pain and nutritional compromise but also creates portals of entry for pathogens, thereby precipitating systemic infections that can interrupt or delay antineoplastic regimens [19–21]. Such delays can adversely influence overall prognosis, including mortality, and drive substantial increases in the cost of care [22]. In this setting, pharmacological and behavioural measures that reduce the oral microbial burden are integral to supportive oncology. Consistent mechanical removal of bacterial plaque is the first-line strategy to minimize microbial challenge during treatment [23,24]. Yet when mucositis is severe, toothbrushing may be unbearably painful or mechanically unsafe, and toothbrushing alone can be inadequate to control plaque. Under these circumstances, adjunctive use of antimicrobial toothpastes and mouthwashes becomes clinically necessary to suppress pathogenic load and limit translocation of microbes [17,25].

Because traumatized mucosa can permit significant bacteraemia during brushing, the interim substitution of an antimicrobial mouthwash—administered before or, if needed, in place of brushing—is often recommended to temper systemic exposure. Multiple reports support chlorhexidine mouthwash as an effective measure both for controlling local infection and for mitigating bacteraemia-related consequences in these vulnerable patients [17,25]. The overarching therapeutic message consonant with this review's title is that careful, protocolized mechanical (brushing and flossing, as tolerated) and chemical (antimicrobial rinses) oral hygiene must be embedded within cancer treatment pathways, with pharmacists collaborating to select agents, manage interactions, and counsel on appropriate dosing and duration.

Despite the centrality of oral health to outcomes, practice variation remains substantial. Barker et al. documented marked differences among centres in their appreciation of oral complications in medically compromised patients, concluding that the evolution of modern cancer therapeutics has been accompanied by an increase in oral adverse events and that systematic medicodental collaboration is indispensable [22]. This observation underscores the pharmacological imperative: antimicrobial stewardship must be harmonized with procedural dentistry, and supportive care regimens should be codified rather than ad hoc. Standardizing mouthcare protocols, ensuring timely dental evaluations, and integrating pharmacy-led medication reviews—particularly around agents that influence mucosal integrity, salivary function, or myelosuppression—are key steps toward reducing preventable interruptions in systemic therapy.

Infectious disorders of the jaws in medically vulnerable populations further illustrate the interface between local pathology and systemic risk. Osteomyelitis of the jaw, while relatively uncommon, occurs with increased frequency among patients with diabetes or those undergoing hemodialysis, where vascular and immunological impairments compromise host response [1]. More recently, osteonecrosis of the mandible has emerged as a clinically challenging entity associated with high-dose or prolonged bisphosphonate therapy.

Bisphosphonates—pyrophosphate analogues that potently inhibit osteoclast-mediated bone resorption—are widely deployed to treat osteoporosis and to palliate skeletal metastases in solid tumors. Yet the same antiresorptive efficacy can impede normal bone remodeling and jaw healing, predisposing

a susceptible subset of patients to necrosis that appears largely irreversible and notoriously difficult to manage [26]. From a pharmacological perspective, this mandates a careful evaluation of the optimal dose and duration of antiresorptive, stratification of individual risk, and pre-treatment dental optimization to minimize post-extraction or post-procedural complications. When osteonecrosis occurs, management is complex and typically requires conservative local care, pain control, and judicious antimicrobial use for superinfection—areas where pharmacist involvement is essential to balance efficacy with toxicity and to anticipate interactions with concurrent oncologic agents.

Cervicofacial actinomycosis represents another, albeit rare, infection that calls for integrated diagnostic vigilance and prolonged pharmacotherapy. Caused predominantly by members of the genus Actinomyces, the disease often presents as a firm mass near the mandible that may invade adjacent bone and muscle and eventually form draining sinus tracts to the skin. Carious teeth, dental interventions, and maxillofacial trauma are recognized sources of inoculation [1,27]. The pathogenesis reflects the capacity of Actinomyces to behave as intracellular parasites and to resist phagocytosis, promoting persistence within tissues. Characteristically, the infection ignores conventional tissue planes and anatomic boundaries, a behaviour that can mimic the infiltrative pattern of malignancy and confound early diagnosis. Effective management typically hinges on a combination of surgical debridement or drainage for source control and extended courses of appropriate antibiotics; here, pharmacy input is pivotal to assure adequate dosing over long durations, to monitor for cumulative toxicity, and to support adherence in the face of complex comorbid regimens.

Taking together, these clinical scenarios affirm the central thesis of this review: the medically compromised patient sits at the nexus of dentistry and pharmacology, where local oral disease can precipitate systemic instability and where systemic therapy can, in turn, amplify oral vulnerability. Preventive dental clearance prior to immunosuppression, cardiac surgery, or prosthetic implantation [14]; routine imaging and expert clinical examination to disclose silent foci; structured plaque control augmented by antimicrobial rinses during periods of mucosal fragility [17,25]; and anticipatory guidance around antiresorptive therapies [26] are not ancillary considerations but core elements of safe, effective medical care. Pharmacists, working in concert with dental and medical colleagues, contribute expertise in antimicrobial selection, interaction management, and supportive care protocols tailored to immunological risk. By embedding these pharmacological approaches within multidisciplinary pathways, clinicians can reduce infection-related morbidity, preserve the continuity of lifesaving therapies, and improve outcomes for patients whose systemic conditions make the mouth both a barometer and a driver of overall health [12,13,15–18,19–21,22,23,24,1,27].

Table 1. Major oral pathogens and pharmacological considerations.

Pathogen/group	**Principal clinical contexts**	**Key properties impacting therapy**	**First-line pharmacological approach**	**Notes/resistance concerns**
Viridans group streptococci	Commensals; source for endocarditis/septicaemia; odontogenic bacteraemia	Frequent transient bacteraemia with routine oral activities	Procedure-led source control; targeted antibiotics when systemic infection occurs	Rising systemic relevance with greater lifetime dentition retention
Facultative anaerobic streptococci	Odontogenic abscess	Mixed aerobic/anaerobic ecology	Penicillin; consider combination with metronidazole in mixed infections	Culture guidance advisable in severe disease
Prevotella spp., Fusobacterium spp.	Odontogenic infections; Lemierre's syndrome	Anaerobes; β-lactamase production common	Penicillin **plus** metronidazole (or equivalent anaerobe-active regimen)	Avoid β-lactam monotherapy when β-lactamase suspected

Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis	Destructive periodontitis	Intracellular invasion; immune evasion	Debridement; consider agents with intracellular penetration; local antimicrobials	Mechanistic links to vascular injury via immune pathways
Actinomyces spp.	Normal plaque scaffold; peri-implantitis; cervicofacial actinomycosis	Biofilm persistence; chronic suppuration	Surgical debridement/drainage + prolonged targeted antibiotics	Peri-implant disease requires mechanical detoxification
Candida albicans and non-albicans	Opportunistic mucosal disease, especially in fragile hosts	Species-specific susceptibility; drug interactions	Topical polyenes/azoles; systemic azoles if refractory	Pharmacist review for CYP-mediated interactions

Significance of Prevention:

The contribution of oral infections to systemic pathology, particularly atherosclerotic cardiovascular disease—has moved from conjecture to a broadly endorsed paradigm grounded in inflammation biology. It is now widely accepted that infection and inflammation are pivotal in initiating and perpetuating endothelial injury, thereby accelerating atherogenesis [28–30]. Chronic inflammatory periodontal diseases, which are ubiquitous across populations and rank among the most prevalent persistent infections in humans, offer a salient model of this oral–systemic interface. Individuals with severe chronic periodontitis demonstrate a significantly elevated risk of cardiovascular events—including atherosclerosis, myocardial infarction, and stroke—even after statistical adjustment for classical risk determinants, underscoring a potentially independent pathogenic signal arising from the periodontal niche [31–33]. For clinicians and pharmacists co-managing cardiometabolic risk, these observations recast periodontal diagnosis and therapy as integral components of systemic vascular care rather than isolated dental concerns.

Since the early investigations originating in Finland, a substantial body of research—now exceeding 50 studies—has examined associations between periodontal disease and cardiovascular outcomes, with the preponderance revealing a significant, albeit modest, positive relationship that persists after controlling for confounders [28–34]. Yet epidemiology, particularly cross-sectional work, is intrinsically limited in adjudicating causality, a caution emphasized by Hujoel et al. [35]. This caveat has sharpened the demand for longitudinal interventional trials and mechanistic studies capable of establishing directional effects. In the interim, short-term interventional studies offer suggestive but important signals: periodontal therapy has been associated with reductions in surrogate markers of cardiovascular risk—most notably interleukin-6 and C-reactive protein—together with improvements in endothelial function and arterial elasticity [36–38]. Translating these findings into pharmacological strategies, pharmacists and dental clinicians can align antimicrobial, anti-inflammatory, and adjunctive regimens with staged periodontal debridement to attenuate systemic inflammatory burden during critical windows of cardiovascular vulnerability.

At the mechanistic level, several non–mutually exclusive pathways plausibly link periodontal pathogens to vascular injury, each with implications for therapeutics addressed in this integrative review. One influential hypothesis invokes molecular mimicry between the bacterial heat-shock protein GroEL and human heat-shock protein 60 (hHSP60). As originally proposed by Wick and colleagues [39,40], immune responses generated against microbial GroEL may cross-react with hHSP60 expressed on stressed or damaged endothelial cells, thus converting a protective antimicrobial response into an autoimmune-like vascular insult. Yamazaki et al. substantiated this model by demonstrating T-cells reactive to both GroEL and hHSP60, with identical T-cell receptor β-chain sequences, within atherosclerotic plaques and periodontal lesions alike [41]. Complementary evidence shows that such cross-reactive T-cells circulate in the peripheral blood of patients with atherosclerosis, and that antibodies to GroEL cross-recognize hHSP60 (and vice versa), thereby furnishing a systemic conduit for endothelial targeting [42,43]. Notably, Porphyromonas gingivalis augments atherosclerosis in animal

models, an effect correlated with heightened levels of anti-GroEL antibodies, which further strengthens the translational relevance of the mimicry paradigm [43]. In clinical practice, these insights support host-modulatory pharmacology—coordinated with local periodontal therapy—to temper maladaptive immune activation while pursuing microbial control.

A second complementary pathway posits direct microbial invasion or translocation into the vascular wall, triggering endothelial activation and atherogenesis. Under physiological conditions, leukocytes do not adhere to intact endothelium; however, infection-induced endothelial perturbation promotes the expression of adhesion molecules that capture circulating white cells. Monocytes are then recruited into the intima, where they ingest oxidized low-density lipoproteins and evolve into lipid-laden foam cells. These foam cells secrete matrix metalloproteinases (MMPs), which degrade extracellular matrix components and weaken the fibrous cap, thereby driving plaque progression and destabilization [44].

The clinical consequences—plaque rupture with downstream myocardial infarction or stroke—align starkly with epidemiological signals linking periodontitis to adverse events. Of particular pharmacological note, tetracycline—an MMP inhibitor—has demonstrated parity with periodontal instrumentation in lowering C-reactive protein among coronary heart disease patients with periodontitis, pointing to an actionable axis of host modulation that can be coordinated by pharmacists within comprehensive care plans [44]. More broadly, the convergence of biomarkers across diabetes, cardiovascular disease, and periodontitis—including C-reactive protein, interleukin-6, tumor necrosis factor-α, and MMP-9—highlights a shared inflammatory transcript that invites harmonized dental–medical pharmacotherapy.

These mechanistic frameworks—molecular mimicry, direct infection of vascular tissues, and immune-inflammatory amplification—should be viewed as synergistic rather than competitive. Collectively, they underscore infection's substantive role in the pathogenesis of atherosclerosis and, by extension, the potential for periodontal therapy to reduce systemic inflammatory tone. Although definitive, long-duration randomised interventions remain limited, the current weight of evidence justifies a prudent, prevention-oriented stance in patients with—or at risk for—coronary heart disease. Within this stance, pharmacological approaches are not merely adjuncts but essential instruments: antimicrobial protocols calibrated to periodontal microbiology; anti-inflammatory and host-modulating agents (including MMP inhibition) deployed judiciously; and meticulous medication reconciliation to mitigate interactions with cardiovascular therapies. Pharmacists, embedded within multidisciplinary teams, can operationalize these strategies by advising on drug selection and dosage, monitoring inflammatory biomarkers where appropriate, and aligning timing of systemic medications with phases of periodontal treatment to limit transient bacteraemia and inflammatory flares.

From a population health perspective, the implications for screening and counselling are immediate. Patients with severe chronic periodontitis warrant targeted cardiovascular risk communication, while those with established cardiovascular disease should be systematically evaluated for periodontal inflammation and treated using protocols that integrate pharmacological and mechanical modalities. Dental professionals can collaborate with cardiologists and primary care physicians to embed oral-health metrics within cardiovascular prevention pathways, and pharmacists can reinforce adherence to both periodontal and cardiometabolic regimens, educate patients on antimicrobial stewardship, and ensure chlorhexidine or other adjuncts are used appropriately when indicated for microbial bioburden control. In acute coronary settings or peri-procedural periods, the team can further coordinate timing of periodontal interventions and optimize anti-platelet and antibiotic strategies to reduce additive risk.

In sum, the significance of oral infections in the development of systemic diseases—with atherosclerotic cardiovascular disease as a leading exemplar—rests on converging epidemiological associations, biologically plausible and increasingly evidenced mechanisms, and interventional signals in surrogate cardiovascular end points [28–30,31–33,28–34,35,36–38,39,40,41,42,43,44]. Even as the field awaits large, definitive longitudinal trials, the clinical prudence of preventing and treating chronic infections such as periodontitis is clear. Bringing dentistry and pharmacy into closer, protocol-driven alignment around antimicrobial, anti-inflammatory, and host-modulating therapies provides a practical, evidence-attuned path to reduce systemic inflammatory load, stabilize endothelial function, and ultimately improve cardiovascular outcomes for patients at risk or living with coronary heart disease.

Prevention Techniques:

Prevention of oral infections occupies a central position because it mitigates both local disease and the systemic inflammatory burden that accompanies chronic oral pathology. Despite decades of public health messaging and clinical guidance, oral infection remains a major global problem. The cornerstone of prevention—effective daily disruption of the dental biofilm—continues to elude a large segment of the population. Even motivated individuals frequently fail to sustain the level, frequency, and technique of plaque control required to maintain periodontal health and to prevent mucosal infection. This persistent implementation gap justifies adjunctive pharmacological strategies within routine home care and professional maintenance programs, and it highlights the importance of close collaboration between dental teams and pharmacists to optimize product selection, educate patients, and steward antimicrobial use responsibly.

At a population level, routine mechanical plaque control (toothbrushing and interdental cleaning) is essential but insufficiently reliable as a sole measure. Hence, a pragmatic and evidence-attuned approach has been to incorporate antimicrobial agents into over-the-counter oral care formulations in order to suppress pathogenic biofilm, reduce gingival inflammation, and stabilize high-risk sites between professional visits. Chlorhexidine has long been regarded as the reference standard for antiseptic efficacy, particularly in short-term applications such as post-procedural care or acute gingival infections. Nevertheless, its well-recognized adverse effects—including taste disturbance, mucosal irritation, and extrinsic tooth staining—limit acceptability and adherence when used over extended periods, constraining its role in long-term, population-wide prevention programs.

Against this backdrop, triclosan has emerged as a viable alternative antimicrobial for sustained use in dentifrices and mouthrinses. Triclosan exhibits broad-spectrum activity against prevalent oral microorganisms and possesses a favorable tolerability profile that supports long-term application in everyday consumer products.

Importantly for integrative dental–pharmacy practice, triclosan's pharmacological attributes extend beyond antibacterial action: it also demonstrates anti-inflammatory effects that are particularly advantageous in conditions dominated by host–microbe interactions at the gingival margin. The cumulative evidence base now encompasses numerous clinical studies demonstrating meaningful reductions in supragingival plaque and gingivitis with triclosan-containing formulations [45]. From the perspective of system-aware prevention, attenuating gingival inflammation has downstream value given the link between periodontal inflammation and broader biomarkers of systemic risk; thus, the dual antimicrobial and anti-inflammatory profile aligns well with the therapeutic aims of this review's integrative remit.

Longitudinal data further reinforce triclosan's preventive relevance. In adults and adolescents with established periodontal involvement, triclosan use has been associated with a slowing of disease progression over 3–5 years, suggesting that sustained chemotherapeutic pressure on the biofilm—paired with routine mechanical control—can temper the trajectory of tissue breakdown [46–48]. Moreover, these benefits are expected to compound with continued use, implying that consistent daily exposure may accrue incremental protective effects at the site level and, by extension, at the patient level [47]. If such effects generalize, the public health implications could be substantial: small but persistent reductions in plaque and inflammation across large populations may translate into measurable decreases in the prevalence and severity of chronic periodontitis, caries secondary to plaque acids, and opportunistic mucosal infections.

Any endorsement of long-term antimicrobial exposure must, however, be balanced against legitimate stewardship concerns. The specter of reduced susceptibility and the emergence of resistant strains has appropriately catalyzed caution in the dental and pharmacy communities. With respect to triclosan used in oral formulations, current evidence indicates no demonstrable selection for triclosan-resistant strains in the clinical context of dentifrices and mouthrinses [49,50]. While ongoing surveillance remains prudent, this finding—taken together with the documented therapeutic benefits—supports the judicious incorporation of triclosan into preventive care plans, especially where mechanical plaque control alone has proved insufficient. In practical terms, this means pharmacists can confidently counsel patients on proper dosing and frequency, screen for potential product overlaps or contraindications in complex regimens and reinforce adherence to maximize clinical gains without compromising antimicrobial stewardship.

A critical nuance for clinicians pursuing pharmacological prevention within the oral–systemic paradigm is patient selection. Evidence suggests that the most pronounced therapeutic benefits of triclosan, particularly with respect to chronic periodontitis, accrue in susceptible individuals and those with pre-existing disease. This observation is consistent with risk-stratified prevention more broadly: patients with higher baseline inflammatory burden or impaired host defenses stand to gain the most from adjunctive chemotherapeutic support.

Medically and immunologically compromised patients—such as those undergoing immunosuppression, living with poorly controlled diabetes, or receiving cytotoxic therapies—constitute an especially vulnerable cohort. It is reasonable to hypothesize that triclosan-containing toothpastes could help stabilize biofilm dynamics and reduce infectious complications in such patients by providing continuous, low-grade antimicrobial and anti-inflammatory action at the mucosal interface. Nonetheless, definitive evidence in these specific populations is still lacking, and rigorously designed studies are needed to determine efficacy, optimal dosing paradigms, and safety profiles in medically compromised contexts.

Operationalizing this prevention strategy within integrated care requires coordinated protocols. Dentists should embed risk assessment into routine examinations, identifying patients whose plaque control remains suboptimal despite instruction and whose periodontal or mucosal findings warrant chemotherapeutic adjuncts. Hygienists can tailor home-care regimens, instructing on correct brushing technique, contact time, and sequence when combining mechanical and chemical approaches. Pharmacists are pivotal in translating product claims into individualized recommendations, ensuring that selected formulations are appropriate for long-term use, compatible with other medications or conditions (e.g., xerostomia management, mucosal sensitivity), and aligned with the patient's capacity for adherence. This interprofessional loop should include outcome monitoring—gingival indices, bleeding scores, and patient-reported ease of use—to calibrate the regimen and discontinue agents that fail to deliver benefit or provoke intolerance.

In sum, prevention of oral infections in the population—and particularly among patients at elevated systemic risk—benefits from integrating pharmacological approaches with sustained behavioral and mechanical strategies. While chlorhexidine remains invaluable for short-term, targeted indications, its side-effect profile limits long-term deployment at scale. Triclosan-containing formulations, validated by reductions in plaque and gingivitis [45] and by attenuation of periodontal disease progression over several years [46–48], offer a practical and well-tolerated long-term alternative, with no current evidence of resistance selection in oral applications [49,50]. The greatest preventive dividends are likely in susceptible or already-affected individuals, with promising—though as yet unproven—applications in medically and immunologically compromised patients. Advancing this agenda will depend on continued collaboration between dentistry and pharmacy to refine product use, safeguard antimicrobial stewardship, and conduct the targeted clinical trials necessary to optimize prevention across the diverse risk spectrum envisioned by this integrative review.

Pharmacological Approaches:

Pharmacological management of oral–systemic diseases integrates pathogen-directed therapy, host modulation, and prevention to reduce both local oral morbidity and the systemic inflammatory burden that propagates cardiovascular, metabolic, and other chronic conditions. Because oral diseases are biofilm-mediated and immuno-inflammatory in nature, effective regimens require careful antimicrobial stewardship, judicious use of anti-inflammatory or immunomodulatory agents, and close coordination between dentists, physicians, and pharmacists to tailor dosing, duration, and sequencing around medical comorbidities and concurrent therapies [51].

The first pillar is targeted at antimicrobial therapy for odontogenic, periodontal, peri-implant, and mucosal infections. Systemic antibiotics are reserved for spreading infections, systemic signs, or high-risk hosts, and are never substitutes for procedural source control. Penicillin-class agents remain foundational for odontogenic infections, with the addition of anaerobe-active agents (e.g., metronidazole) when β-lactamase–producing anaerobes are suspected.

Alternatives for β-lactam allergy must weigh efficacy against safety: clindamycin's historical use is increasingly tempered by Clostridioides difficile and resistance concerns, prompting preference for other classes when appropriate. For periodontal disease, locally delivered antimicrobials—such as

doxycycline gels, minocycline microspheres, or chlorhexidine inserts—achieve therapeutic concentrations within periodontal pockets while minimizing systemic exposure.

In peri-implantitis, antiseptic decontamination and locally delivered antibiotics can be considered adjuncts to mechanical and surgical therapy, recognizing biofilm-associated tolerance and the need for debridement. For fungal disease, topical polyenes (nystatin) or azoles (clotrimazole) treat uncomplicated candidosis, whereas fluconazole or itraconazole are reserved for refractory or systemically at-risk patients, with pharmacists monitoring for cytochrome P450–mediated interactions (e.g., with anticoagulants, statins, or immunosuppressants). Episodic or prophylactic antivirals (acyclovir, valacyclovir) are appropriate for immunocompromised patients with recurrent herpetic disease or following mucosal trauma.

A second pillar comprises host-modulation therapies that temper dysregulated inflammation and matrix breakdown central to periodontitis and peri-implant disease. Subantimicrobial-dose doxycycline (SDD) inhibits matrix metalloproteinases without exerting conventional antibacterial selection pressure and serves as an adjunct for patients with persistent inflammatory burden after debridement. Short courses of nonsteroidal anti-inflammatory drugs may transiently reduce gingival inflammation, but long-term use is limited by gastrointestinal, renal, and cardiovascular risks; thus, emphasis falls on agents with favorable safety profiles or localized delivery. Emerging approaches—such as specialized pro-resolving mediators and locally applied statins—seek to enhance resolution of inflammation and soft- and hard-tissue repair; although early data are promising, they require further confirmatory trials before routine use. Throughout, pharmacists contribute by assessing contraindications, drug–drug interactions, and patient-specific risk, especially in polypharmacy and multimorbidity.

A third domain addresses the bidirectional links between periodontitis and systemic conditions, particularly diabetes, atherosclerotic cardiovascular disease, adverse pregnancy outcomes, and rheumatoid arthritis. Periodontal therapy reduces surrogate markers of systemic inflammation (e.g., C-reactive protein) and may confer modest improvements in endothelial function and glycaemic indices. Pharmacologically, aligning anti-infective and host-modulating regimens with optimization of systemic medications—intensifying antihyperglycaemic therapy in poorly controlled diabetes, ensuring statin adherence in high cardiovascular risk, or coordinating biologic disease-modifying agents in rheumatoid arthritis—can amplify periodontal gains and stabilize systemic status. Conversely, systemically targeted biologics (e.g., TNF-α inhibitors) can attenuate oral inflammatory signs in susceptible patients. Such cross-disciplinary synchronization is most effective when pharmacists manage timing (e.g., debridement during periods of lower immunosuppression), mitigate interaction risks (e.g., azole antifungals with calcineurin inhibitors), and recommend prophylaxis where appropriate [51].

Supportive care pharmacology is equally crucial in oncology and other medically complex settings. To prevent and treat cancer therapy–related oral mucositis, protocols incorporate benzydamine mouthrinses, cryotherapy for certain chemotherapeutics, palifermin in selected hematologic indications, and rigorous pain management (topical anesthetics, systemic analgesics). Antimicrobial mouthrinses (chlorhexidine, essential oils, cetylpyridinium chloride) reduce microbial load when mechanical hygiene is limited by pain; however, long-term chlorhexidine is constrained by dysgeusia and staining. In xerostomia from head-and-neck radiotherapy or anticholinergic medications, sialogogues (pilocarpine, cevimeline) and saliva substitutes, alongside high-fluoride toothpaste and varnishes, mitigate caries risk and mucosal susceptibility to infection.

Pre-treatment dental clearance and elimination of oral foci before myelosuppressive therapy, solid-organ transplantation, or initiation of potent antiresorptives (bisphosphonates, denosumab) reduce the risk of sepsis and medication-related osteonecrosis; when antiresorptives are unavoidable, conservative dental strategies and antimicrobial coverage for superinfection are considered case-by-case.

Preventive pharmacology extends to population-level measures that stabilize the biofilm and gingival inflammation between professional visits. Antimicrobial dentifrices and mouthrinses (e.g., triclosan- or essential oil–containing formulations, cetylpyridinium chloride) can reduce plaque and gingivitis in individuals unable to achieve adequate mechanical control, while high-fluoride dentifrices, fluoride varnish, and silver diamine fluoride curb caries progression in root-caries-prone or medically compromised patients. Probiotic and prebiotic strategies targeting the oral microbiome are under investigation; although evidence is heterogeneous, they represent a low-risk adjunct in carefully selected

patients. Pharmacists reinforce adherence, counsel on correct use (contact time, frequency), and watch for cumulative exposure to overlapping antiseptics across products.

Across all domains, antibiotic stewardship is non-negotiable. Empiric choices should reflect local resistance patterns and individual risk; durations should be as short as clinically effective; and escalation to broader agents requires culture-guided justification. Clinicians must balance benefits against adverse effects such as C. difficile infection, QT prolongation with certain macrolides or fluoroquinolones, photosensitivity with tetracyclines, and teratogenicity or tooth discoloration risks in pregnancy and childhood. Equally, prophylaxis for infective endocarditis is now restricted to narrowly defined high-risk cardiac conditions; indiscriminate prophylaxis is discouraged [51].

Robust medication reconciliation—capturing anticoagulants, antiplatelets, immunosuppressants, and herbal supplements—prevents hemorrhagic or infectious complications around dental procedures and guides peri-operative bridging strategies where indicated. In practice, optimal outcomes arise from a structured, interprofessional model: dentists provide mechanical and surgical control of disease; physicians manage systemic comorbidities; and pharmacists orchestrate pharmacotherapy—selecting the right drug, dose, route, and duration; anticipating interactions; and coaching adherence and adverse-event surveillance. This integrated pharmacological approach not only resolves oral infections more reliably but also attenuates systemic inflammation, stabilizes vulnerable patients during periods of medical therapy, and ultimately advances whole-person health [51].

Table 2. Pharmacological approaches by clinical scenario.

Clinical scenario	Primary goals	Procedural cornerstone	Pharmacological adjuncts	Special notes
Odontogenic infection	Rapid source control; prevent spread/airway risk	Drainage, debridement, endodontics/extraction	Penicillin + metronidazole; culture-guided refinement	Airway vigilance; manage interactions in critical care
Periodontitis	Reduce inflammation and tissue breakdown	Scaling and root planing; maintenance	Local antimicrobials; subantimicrobial-dose doxycycline	Monitor systemic markers in high-risk patients
Peri-implantitis	Halt bone loss; preserve implant	Mechanical decontamination; surgery as needed	Local antibiotics/antiseptics	Biofilm tolerance limits systemic antibiotics
Cancer therapy–related mucositis	Maintain nutrition/therapy schedules	Oral care protocols; cryotherapy where indicated	Benzydamine rinses; analgesics; antimicrobial rinses; antifungals/antivirals as needed	Use rinses before/instead of brushing when bleeding/painful
Oral candidosis	Eradicate infection; prevent recurrence	Gentle debridement of removable appliances	Nystatin/clotrimazole; fluconazole for refractory disease	Screen interactions (e.g., azoles with anticoagulants)
MRONJ risk (antiresorptives)	Prevent osteonecrosis; control pain	Pre-treatment dental clearance	Conservative antibiotics for superinfection; analgesia	Individualize around dose/duration of antiresorptives

Collaboration Among Pharmacists and Dentists:

Effective management of oral–systemic diseases demands a deliberately interprofessional model in which dentists and pharmacists function as co-equal partners across assessment, treatment, and prevention. Their collaboration spans antimicrobial stewardship, host-modulatory pharmacotherapy, peri-procedural planning, management of therapy-induced oral toxicities, and longitudinal risk reduction. Because oral pathology is fundamentally biofilm-mediated and immuno-inflammatory, no single discipline can optimize outcomes in isolation; coordinated, protocol-driven teamwork is essential to reduce local disease activity and the systemic inflammatory burden that amplifies cardiometabolic and other chronic conditions.

A primary arena for collaboration is antimicrobial therapy. Dentists establish source control through mechanical and surgical interventions, while pharmacists ensure the antimicrobial regimen is pathogen-concordant, appropriately dosed, and as short as clinically effective. Joint decision-making is particularly important for odontogenic infections with anaerobic involvement, peri-implantitis with biofilm-associated tolerance, and refractory periodontitis requiring adjunctive local delivery systems. Pharmacists evaluate allergy histories, renal and hepatic function, and local resistance patterns; they also mitigate risks associated with agents of concern (e.g., clindamycin's Clostridioides difficile risk) and recommend safer alternatives when indicated. For locally delivered antimicrobials—such as chlorhexidine chips, minocycline microspheres, or doxycycline gels—pharmacists reinforce correct administration schedules, counsel on expected effects and potential staining or dysgeusia, and monitor for cumulative exposure when patients also use antiseptic mouthrinses or medicated dentifrices [51].

Host-modulation is a second domain that benefits from shared stewardship. Subantimicrobial-dose doxycycline to inhibit matrix metalloproteinases, short courses of topical or systemic anti-inflammatories in carefully selected cases, and emerging agents that promote resolution of inflammation all require nuanced balancing of benefit and risk. Pharmacists contribute pharmacokinetic expertise, screen for drug–drug interactions (e.g., NSAIDs with anticoagulants or antihypertensives), and tailor dosing to comorbid renal or hepatic impairment. Dentists, in turn, synchronize pharmacological adjuncts with debridement and maintenance intervals, using clinical indices to determine when escalation or de-escalation is justified. Jointly, the team can implement biomarker-guided strategies—where available—to align therapy intensity with inflammatory burden.

The peri-procedural care of medically complex patients is a third locus of integration. Before myelosuppressive chemotherapy, solid-organ transplantation, or initiation of potent antiresorptives or antiangiogenics, pharmacists and dentists collaborated on dental clearance pathways to eliminate oral foci that could precipitate sepsis or medication-related osteonecrosis of the jaw. Pharmacists flag high-risk drug exposures, advise on drug holidays only where evidence supports them, and coordinate timing to minimize additive immunosuppression or bleeding risk. In patients on antithrombotic therapy, the pharmacist's review of anticoagulants and antiplatelets informs dental planning around minor surgery, local hemostatic measures, and, when necessary, prescriber-led peri-operative adjustments; indiscriminate interruption is avoided to reduce thromboembolic risk. For infective endocarditis prophylaxis, pharmacists reinforce contemporary criteria, ensuring antibiotics are reserved for narrowly defined cardiac indications and dosed correctly [51].

Oncology and complex medical therapeutics create additional demands that are best met collaboratively. Cancer therapy–related oral mucositis, xerostomia, opportunistic candidosis, and herpetic reactivation require layered pharmacological support. Dentists diagnose and stage toxicities, while pharmacists assemble evidence-based regimens—benzydamine rinses where indicated, antifungals with careful attention to cytochrome P450 interactions, prophylactic or episodic antivirals in immunocompromise, and sialogogues in salivary hypofunction—tailored to the patient's other medications and organ function. Where pain limits mechanical plaque control, pharmacists recommend antiseptic alternatives and counsel on sequence of care (analgesic, rinse, then gentle hygiene) to reduce bacteraemia risk and preserve adherence to antineoplastic schedules.

Medication-induced oral conditions further illustrate the value of bidirectional communication. Gingival overgrowth from calcium channel blockers or cyclosporine, lichenoid reactions from certain antihypertensives or antimalarials, and xerostomia from anticholinergics undermine periodontal stability and accelerate caries. Dentists identify the phenotype, document severity, and propose dental adaptations; pharmacists evaluate substitution possibilities with the prescribing physician, anticipate withdrawal or titration issues, and counsel on adjuncts such as high-fluoride toothpaste, remineralizing

agents, and saliva substitutes. This triadic dialogue prevents therapeutic nihilism and often yields safer, equally effective systemic regimens with fewer oral adverse effects.

Community and hospital pharmacists also serve as front-line sentinels for dental presentations within the broader health system. Many patients first seek help for dental pain at pharmacies; standardized referral algorithms developed with dentists can triage red-flag conditions (e.g., spreading infection, trismus, systemic signs) for urgent dental care while providing short-term analgesic guidance consistent with opioid stewardship and gastrointestinal safety. Pharmacists can counter inappropriate antibiotic demands by explaining that antibiotics do not substitute for drainage or debridement, thereby aligning public expectations with best practice and curbing resistance selection pressure.

Operationalizing these collaborations requires shared infrastructure and governance. Integrated medication reconciliation, dental–medical EHR interoperability, and closed-loop communication about treatment plans, laboratory values, and adverse events reduce errors and delays. Collaborative practice agreements can authorize pharmacists to adjust certain oral-care adjuncts, manage rinse protocols, and order relevant labs (e.g., renal function for antifungal dosing), while dentists retain responsibility for diagnosis and procedural care. Joint clinical pathways—for periodontal therapy in poorly controlled diabetes, for example—link debridement schedules to pharmacological intensification periods, glycaemic monitoring, and reinforcement of statin and antihypertensive adherence, producing concurrent improvements in oral and systemic metrics [51].

Finally, sustained quality improvement and research should be co-led. Pharmacists can maintain antimicrobial-use dashboards, track resistance trends in odontogenic pathogens, and audit adherence to endocarditis-prophylaxis criteria; dentists can contribute clinical outcomes, radiographic progression data, and patient-reported measures. Together they can design pragmatic trials testing combinations of mechanical therapy and host-modulating agents, evaluate deprescribing of xerogenic drugs with oral outcomes as endpoints, and refine cost-effective mouthcare bundles in oncology. Interprofessional education—shared case conferences, rotations, and simulation—cements of common vocabulary and accelerates adoption of evidence-based practices [51].

In sum, collaboration between pharmacists and dentists transforms fragmented interventions into coherent, patient-centered strategies that align pharmacotherapy with procedural excellence. This partnership elevates antimicrobial stewardship, mitigates drug-related oral morbidity, safeguards complex medical treatments from oral complications, and measurably reduces the systemic inflammatory footprint of oral disease.

Table 3. Prevention strategies and antiseptic options.

Strategy/agent	Indications	Advantages	Limitations/adverse effects	Evidence highlights
Mechanical plaque control (brushing/interdental)	Universal baseline	Low cost; foundational	Adherence/technique dependent	Essential but often insufficient alone
Chlorhexidine rinses	Short-term infection control; peri-procedural	Broad antisepsis; bacteraemia mitigation	Staining, dysgeusia, irritation (limits long-term use)	Effective for acute phases

Strategy/agent	Indications	Advantages	Limitations/adverse effects	Evidence highlights
Triclosan-containing dentifrices	Long-term plaque/gingivitis control; susceptible patients	Antimicrobial + anti-inflammatory; well tolerated	Stewardship considerations	Reduces plaque/gingivitis; slows periodontal progression over 3–5 years
Cetylpyridinium/essential oils	Adjunct plaque control	Over-the-counter access	Variable potency	Useful for maintenance when brushing limited
High-fluoride dentifrices/varnish; SDF	Caries prevention, root caries	Remineralization; non-invasive arrest	Cosmetic staining with SDF	Valuable in medically compromised or xerostomic patients

Conclusion:

Pharmacological management of oral–systemic diseases succeeds when it is explicitly integrated with procedural dentistry and individualized to a patient's systemic context. Across conditions—from rapidly spreading odontogenic infections to chronic periodontitis, peri-implantitis, and therapy-induced mucosal disease, the constant is source control paired with judicious, pharmacist-guided pharmacotherapy. Narrow-spectrum, culture-concordant antibiotic regimens (e.g., penicillin with metronidazole for anaerobe-rich infections) should be preferred over empiric broad coverage, with careful attention to allergy histories, organ function, and drug–drug interactions. In periodontal and peri-implant disease, locally delivered antimicrobials and host-modulatory agents, such as Subantimicrobial-dose doxycycline, provide targeted control of biofilm and matrix degradation while limiting systemic exposure.

Supportive oncology illustrates the stakes of coordinated care: pre-treatment dental optimization, antimicrobial mouthrinses during mucositis, and vigilant antifungal/antiviral prophylaxis preserve antineoplastic dosing schedules and reduce hospitalizations. Likewise, anticipatory strategies around antiresorptive or immunosuppressive therapy mitigate the risks of osteonecrosis and sepsis. Prevention remains foundational; while chlorhexidine retains a role for short-term indications, long-term population-level control of plaque and gingival inflammation is better served by well-tolerated formulations (e.g., triclosan-containing dentifrices) embedded within risk-stratified home-care protocols.

The broader systemic dividend is nontrivial: periodontal therapy and well-executed pharmacological adjuncts correspond with reductions in systemic inflammatory biomarkers and improvements in endothelial function, aligning oral care with cardiovascular and metabolic risk modification. Advancing these gains requires standardized interprofessional pathways, electronic shared records, and continuous audit of antimicrobial use and outcomes. Future research should prioritize pragmatic trials that couple mechanical debridement with host modulation, evaluate deprescribing of xerogenic agents using oral endpoints, and refine cost-effective care bundles for medically complex populations. In sum, pharmacist–dentist collaboration converts fragmented measures into coherent, safe, and effective therapy that improves both oral and overall health.

References:

1. Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Edinburgh: Churchill Livingstone; 2005.
2. Ylijoki S, Suuronen R, Jousimies-Somer H, et al. Differences between patients with or without the need for intensive care due to severe odontogenic infections. J Oral Maxillofac Surg. 2001;59:867–872.
3. Rudney JD, Chen R, Sedgewick GJ. Intracellular Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in buccal epithelial cells collected from human subjects. Infect Immun. 2001;69:2700–2707.
4. Rautemaa R, Järvensivu A, Kari K, et al. Intracellular localization of Porphyromonas gingivalis thiol proteinase in periodontal tissues of chronic periodontitis patients. Oral Dis. 2004;10:298–305.
5. Sarkonen N, Könönen E, Eerola E, et al. Characterization of Actinomyces species isolated from failed dental implant fixtures. Anaerobe. 2005;11:231–237.
6. Rousseau MC, Harle JR. Spondylitis caused by Peptostreptococcus. Clin Rheumatol. 1998;17:538–539.
7. Gendron R, Grenier D, Maheu-Robert L. The oral cavity as a reservoir of bacterial pathogens for focal infections. Microb Infect. 2000;2:897–906.
8. Huang ST, Lee HC, Lee NY, et al. Clinical characteristics of invasive Haemophilus aphrophilus infections. J Microbiol Immunol Infect. 2005;38:271–276.
9. Vargas J, Hernandez M, Silvestri C, et al. Brain abscess due to Arcanobacterium haemolyticum after dental extraction. Clin Infect Dis. 2006;42:1810–1811.
10. Lockhart PB, Brennan MT, Kent ML, et al. Impact of amoxicillin prophylaxis on the incidence, nature and duration of bacteremia in children after intubation and dental procedures. Circulation. 2004;109:2878–2884.
11. Rajasuo A, Nyfors S, Kanervo A, et al. Bacteremia after plate removal and tooth extraction. Int J Oral Maxillofac Surg. 2004;33:356–360.
12. Foschi F, Izard J, Sasaki H, et al. Treponema denticola in disseminating endodontic infections. J Dent Res. 2006;85:761–765.
13. Yamagata K, Onizawa K, Yanagawa T, et al. A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:237–242.
14. Curry S, Phillips H. Joint arthroplasty, dental treatment, and antibiotics: a review. J Arthroplasty. 2002;17:111–113.
15. National Institute of Health Development panel. Consensus statement: oral complications of cancer therapy. NCI Monogr. 1990;9:3–8.
16. Meurman JH, Laine P, Murtomaa H, et al. Effect of antiseptic mouthwashes on some clinical and microbiological findings in the mouths of lymphoma patients receiving cytostatic drugs. J Clin Periodontol. 1991;18:587–591.
17. Levy-Polack MP, Sebelli P, Polack NL. Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec Care Dentist. 1998;18:189–193.
18. Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer. 2004;40:1208–1216.

19. Bergmann O. Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J Clin Microbiol. 1988;26:2105–2109.
20. Heimdahl A, Mattsson T, Dahllöf G, et al. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1989;68:711–716.
21. Melkos AB, Massenkeil G, Arnold R, et al. Dental treatment prior to stem cell transplantation and its influence on the posttransplantation outcome. Clin Oral Investig. 2003;7:113–115.
22. Barker GJ, Epstein JB, Williams KB, et al. Current practice and knowledge of oral care for cancer patients: a survey of supportive health care providers. Support Care Cancer. 2005;13:32–41.
23. McGuire DB, Correa ME, Johnson J, et al. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14:541–547.
24. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–831.
25. Costa EM, Fernandes MZ, Quinder LB, et al. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003;17:147–150.
26. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope. 2007;117:30–34.
27. Cohen J, Powderly WG, editors. Infectious Diseases. London: Mosby; 2004.
28. Syrjänen J, Valtonen VV, Iivanainen M, et al. Preceding infection as an important risk factor for ischemic brain infarction in young and middle aged patients. BMJ. 1988;296:1156–1160.
29. Grau AJ, Buggle F, Heindl S, et al. Recent infection as a risk factor for cerebrovascular ischemia. Stroke. 1995;26:373–379.
30. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J. 1996;17:682–688.
31. DeStefano F, Anda RF, Kahn S, et al. Dental disease and the risk of coronary heart disease and mortality. BMJ. 1993;306:688–691.
32. Grau A, Buggle F, Ziegler C, et al. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke. 1997;28:1724–1729.
33. Valtonen VV. Role of infections in atherosclerosis. Am Heart J. 1999;138:S431–S433.
34. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and acute myocardial infarction. BMJ. 1989;25:779–781.
35. Hujoel PP, Drangsholt M, Spiekerman C, et al. Periodontal disease and coronary heart disease risk. JAMA. 2000;248:1406–1410.
36. Amar S, Gokce N, Morgan S, et al. Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol. 2003;23:1245–1249.
37. Mercanoglu F, Oflaz H, Oz O, et al. Endothelial dysfunction in patients with chronic periodontitis and its improvement after initial periodontal therapy. J Periodontol. 2004;75:1694–1700.
38. Tonetti MS, D'Aiuto F, Nibali L, et al. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356:911–920.
39. Wick G, Perschinka H, Xu Q. Autoimmunity and atherosclerosis. Am Heart J. 1999;138:S444–S449.
40. Wick G. Atherosclerosis—an autoimmune disease due to an immune reaction against heat-shock protein 60. Herz. 2000;25:87–90.
41. Yamazaki K, Ohsawa Y, Tabeta K, et al. Accumulation of human heat shock protein 60-reactive cells in the gingival tissues of periodontitis patients. Infect Immun. 2002;70:2492–2501.
42. Ford PJ, Gemmell E, Walker PJ, et al. Characterization of heat shock protein-specific T cells in atherosclerosis. Clin Diagn Lab Immunol. 2005;12:259–267.
43. Ford PJ, Gemmell E, Timms P, et al. Anti-P. gingivalis response correlates with atherosclerosis. J Dent Res. 2007;86:35–40.
44. Sorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med. 2006;38:306–321.
45. Volpe AR, Petrone ME, DeVizio W, et al. A review of plaque, gingivitis, calculus and caries clinical efficacy studies with a fluoride dentifrice containing triclosan and PVM/MA copolymer. J Clin Dentistry. 1996;7:S1–S14.

46. Rosling B, Wannfors B, Volpe AR, et al. The use of a triclosan/copolymer dentifrice may retard the progression of periodontitis. J Clin Periodontol. 1997;24:873–880.
47. Cullinan MP, Westerman B, Hamlet SM, et al. The effect of a triclosan-containing dentifrice on the progression of periodontal disease in an adult population. J Clin Periodontol. 2003;30:414–419.
48. Ellwood RP, Worthington HV, Blinkhorn ASB, et al. Effect of a triclosan/copolymer dentifrice on the incidence of periodontal attachment loss in adolescents. J Clin Periodontol. 1998;25:363–367.
49. Cullinan MP, Hamlet SM, Westerman B, et al. Acquisition and loss of Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Prevotella intermedia over a 5-year period: effect of a triclosan/copolymer dentifrice. J Clin Periodontol. 2003;30:532–541.
50. Rosling B, Dahlén G, Volpe A, et al. Effect of triclosan on the subgingival microbiota of periodontitis-susceptible subjects. J Clin Periodontol. 1997;24:881–887.
51. Awaji WH, Alnafeesi NM, Alotaibi AD, Faris SA, Arawi MA, Alqurashi SA, Alanazi HD, Almutairi MA, Alhatlani SA, Alsaghir ZA, Al Yami AS. Oral Health and Systemic Diseases: A Collaborative Perspective from Dentistry, Pharmacy, and Health Informatics. Journal of International Crisis and Risk Communication Research. 2024;7(S9):2794.

النهوج الدوائية للأمراض الفموية–الجهازية: مراجعة سريرية تدمج طب الأسنان والصيدلة

الملخص

الخلفية: تُعدّ أمراض الفم حالاتٍ ناتجة عن اللويحة الجرثومية واستجابات التهابية مناعية، وقد تستمر حتى الشيخوخة وتعمل كمستودعات للعدوى والالتهاب الجهازي. وتفرض بيئتها الميكروبية—من اللاهوائيات المنتِجة لبيتا-لاكتاماز (Prevotella و Fusobacterium) إلى مسببات أمراض لثوية داخل خلوية (Aggregatibacter actinomycetemcomitans و Porphyromonas gingivalis) والفطور الانتهازية—(Candida spp.) تحديات علاجية تتطلب حُسن ترشيد للمضادات وتعاوناً بين المهنيين.

الهدف: تلخيص النهوج الدوائية للوقاية من الأمراض الفموية–الجهازية ومعالجتها، بدمج الإجراءات السنية مع استراتيجيات دوائية موجهة يقودها الصيدلي، مع التركيز على المرضى عاليي الخطورة وتخفيف المخاطر القلبية الوعائية.

الطرق: مراجعة سردية سريرية لبيئة الممرضات، وآليات المرض، ونماذج العلاج عبر الإنتانات السنية المنشأ، وأمراض اللثة والغرسات، وتسممات علاج السرطان، والوقاية الدوائية، مع إبراز أطر التعاون بين طب الأسنان والصيدلة.

النتائج: يعتمد النجاح على ضبط المصدر الإجرائي مدعوماً بعلاج دوائي موجّه (مثل البنسلين مع ميترونيدازول عند الاشتباه ببيتا-لاكتاماز)، وعلى التطبيقات الموضعية داخل الجيوب اللثوية، ومعالجة المبيضات مع مراقبة التداخلات، والفيروسات بالعوامل المضادة المناسبة. يخفّف تعديل الاستجابة المضيفة (مثل الجرعات دون العلاجية للدوكسيسيكلين) من هدم المصفوفة. يقلّل التحضير السني المسبق مخاطر الإنتان والنخر العظمي لدى المثبَّطي المناعة أو متلقي مضادات الارتشاف. وقائياً، يُمزَج ضبط اللويحة الميكانيكي مع مطهرات مساندة؛ ويحدّ تأثيرات الكلورهيكسيدين من استعماله الطويل، بينما تُظهر معاجين التريكلوسان خفضاً مستديماً للّويحة/التهاب اللثة وإبطاءً لتقدم المرض. ترتبط المعالجة اللثوية بانخفاض الواسمات الالتهابية وتحسن وظيفة البطانة.

الاستنتاج: تُخفِّض الاستراتيجيات الدوائية، ضمن تعاون منظّم بين طبيب الأسنان والصيدلي، العبء الإنتاني الفموي والالتهاب الجهازي وتحمي العلاجات الطبية المعقدة. إن توحيد البروتوكولات ورصد النتائج ضروريان لتحسين صحة المريض الشاملة.

الكلمات المفتاحية: الارتباط الفموي–الجهازي؛ ترشيد المضادات؛ أمراض اللثة؛ إنتان سني المنشأ؛ التهاب حول الغرسة؛ داء المبيضات؛ تعديل الاستجابة المضيفة؛ كلورهكسيدين؛ تريكلوسان؛ رعاية بين-مهنية.